Company intelligence / Profile preview

Sparkline

Philadelphia, Pennsylvania, USAsparkline.com ↗

Ownership: Private
Employees: ~800
Development stage: Other

Overview

Spark Therapeutics developed Luxturna (voretigene neparvovec), the first FDA-approved gene therapy for an inherited disease (RPE65-mediated retinal dystrophy). The company has additional gene therapies in development targeting hemophilia A/B and central nervous system diseases. It operates as a subsidiary of Roche since its $4.3–$4.8 billion acquisition in late 2019/early 2020.

Therapeutic areas: OphthalmologyHematology
Modalities: Gene therapyBiologic
Industry: Biotech

Partnerships

Roche (parent)

Beyond the preview

Go deeper on Sparkline.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Sparkline.

Explore the full profile